Mary Thistle is a biopharmaceutical leader with over 20 years of experience in the life sciences industry, having held senior finance, operations, and business development roles. Currently, Mary serves as a Director at Vigil Neuroscience, Aktis Oncology, Entrada Therapeutics, and Q32 Bio Inc., and is also on the Board of Directors for Enterome SA, Homology Medicines, and Ziopharm Oncology. Previously, Mary was a Chief Operating Officer at Dimension Therapeutics and a Special Advisor to the Bill and Melinda Gates Medical Research Institute. Holding a BS in Accounting and Business/Management, Summa cum laude, from UMass Boston, Mary has made significant contributions to various organizations, including leading M&A activities and enhancing operational efficiencies.
This person is not in the org chart
This person is not in any teams
This person is not in any offices